Skip to main content
padlock icon - secure page this page is secure

Pathophysiological aspects of red blood cells in end‐stage renal disease patients resistant to recombinant human erythropoietin therapy

Buy Article:

$59.00 + tax (Refund Policy)

Modified, bioreactive red blood cells (RBCs) and RBC‐derived microvesicles (MVs) likely contribute to the hematological and cardiovascular complications in end‐stage renal disease (ESRD). This study assesses the physiological profile of RBCs in patients with ESRD receiving standard or high doses of recombinant human erythropoietin (rhEPO).
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: end‐stage renal disease; hemodialysis; recombinant human erythropoietin; red blood cells; rhEPO resistance

Document Type: Research Article

Publication date: June 1, 2017

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more